يعرض 1 - 3 نتائج من 3 نتيجة بحث عن '"Kyran, EL"', وقت الاستعلام: 2.99s تنقيح النتائج
  1. 1
    دورية أكاديمية
    The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models

    المؤلفون: Ho, GY, Vandenberg, CJ, Lim, R, Christie, EL, Garsed, DW, Lieschke, E, Nesic, K, Kondrashova, O, Ratnayake, G, Radke, M, Penington, JS, Carmagnac, A, Heong, V, Kyran, EL, Zhang, F, Traficante, N, Huang, R, Dobrovic, A, Swisher, EM, McNally, O, Kee, D, Wakefield, MJ, Papenfuss, AT, Bowtell, DDL, Barker, HE, Scott, CL

    العلاقة: NHMRC/400281; NHMRC/400413; NHMRC/1081178; pii: 10.1177_17588359231208674; Ho, G. Y., Vandenberg, C. J., Lim, R., Christie, E. L., Garsed, D. W., Lieschke, E., Nesic, K., Kondrashova, O., Ratnayake, G., Radke, M., Penington, J. S., Carmagnac, A., Heong, V., Kyran, E. L., Zhang, F., Traficante, N., Huang, R., Dobrovic, A., Swisher, E. M. ,. Scott, C. L. (2023). The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 15, https://doi.org/10.1177/17588359231208674Test.; http://hdl.handle.net/11343/344499Test

    الإتاحة: https://doi.org/10.1177/17588359231208674Test
    http://hdl.handle.net/11343/344499Test

    View record in BASE النص الكامل

    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin

    المؤلفون: Ho, GY, Kyran, EL, Bedo, J, Wakefield, MJ, Ennis, DP, Mirza, HB, Vandenberg, CJ, Lieschke, E, Farrell, A, Hadla, A, Lim, R, Dall, G, Vince, JE, Chua, NK, Kondrashova, O, Upstill-Goddard, R, Bailey, U-M, Dowson, S, Roxburgh, P, Glasspool, RM, Bryson, G, Biankin, AV, Cooke, SL, Ratnayake, G, McNally, O, Traficante, N, DeFazio, A, Weroha, SJ, Bowtell, DD, McNeish, IA, Papenfuss, AT, Scott, CL, Barker, HE

    العلاقة: NHMRC/1081178; NHMRC/1062702; NHMRC/400281; NHMRC/400413; pii: 709667; Ho, G. Y., Kyran, E. L., Bedo, J., Wakefield, M. J., Ennis, D. P., Mirza, H. B., Vandenberg, C. J., Lieschke, E., Farrell, A., Hadla, A., Lim, R., Dall, G., Vince, J. E., Chua, N. K., Kondrashova, O., Upstill-Goddard, R., Bailey, U. -M., Dowson, S., Roxburgh, P. ,. Barker, H. E. (2022). Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin. CANCER RESEARCH, 82 (23), pp.4457-4473. https://doi.org/10.1158/0008-5472.CAN-21-4012Test.; http://hdl.handle.net/11343/320081Test

    الإتاحة: https://doi.org/10.1158/0008-5472.CAN-21-4012Test
    http://hdl.handle.net/11343/320081Test

    View record in BASE النص الكامل

    أضف إلى المفضلة
  3. 3
    Ovarian carcinosarcoma genomics and pre-clinical models highlight the N-MYC pathway as a key driver and susceptibility to EMT-targeting therapy

    المؤلفون: Elizabeth Lieschke, Suzanne Dowson, Susie Cooke, Gareth Bryson, Andrew V. Biankin, Kyran El, Anna deFazio, Olga Kondrashova, John Weroha, Justin Bedo, Orla McNally, Iain A. McNeish, Ulla-Maja Bailey, Clare L. Scott, Nadia Traficante, Matthew Wakefield, H. B. Mirza, Holly E. Barker, Rosie Upstill-Goddard, Rosalind Glasspool, Darren Ennis, Cassandra J. Vandenberg, Patricia Roxburgh, Anthony T. Papenfuss, Gayanie Ratnayake, David D.L. Bowtell, Gwo-Yaw Ho

    مصطلحات موضوعية: business.industry, medicine.medical_treatment, Mesenchymal stem cell, Immunotherapy, medicine.disease, Vinorelbine, chemistry.chemical_compound, chemistry, Monoclonal, Cancer research, medicine, Carcinoma, Sarcoma, business, Ovarian Carcinosarcoma, medicine.drug, Eribulin

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::dc1e598cf60eac20e8ce12ed81c5d9feTest
    https://doi.org/10.1101/2020.11.24.396796Test


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث